FDA approves brexucabtagene autoleucel for adult patients with relapsed or refractory mantle cell lymphoma

The FDA approved this chimeric antigen receptor (CAR) T cell therapy adult patients diagnosed with mantle cell lymphoma who have not responded to or who have relapsed following other kinds of treatment. It was filed for regulatory review in the EU in January this year.

Source:

Biospace Inc.